MUSTANG BIO, INC. (MBIO)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$16.3M
Cash & Equivalents
$1.0M
Quarterly Burn Rate
48 mo
Est. Cash Runway
$5M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-08-06 Phase1 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT02159495 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persi... PHASE1 Active Not Recruiting 31

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for MBIO.

SEC EDGAR Filings

All SEC filings for MUSTANG BIO, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.